Monitor both patient access and the evidence supporting the arrangement. The following is a proposed operating cadence, not a regulatory schedule.
| Cadence | Review | Action |
|---|---|---|
| Daily during pilot or disruption | Orders due, unacknowledged prescriptions, paid unshipped orders, delivery exceptions | Assign owners and escalate time-sensitive cases |
| Weekly | Fulfilment by state/product; backlog age; support effort; replacement and refund reconciliation | Correct workflow and capacity failures |
| Monthly | Clinic cost, patient-cost changes, supplier concentration, commitments and evidence expiries | Reforecast and review commercial exposure |
| Before renewal or expansion | Current licences, facility changes, programme terms, quality evidence and fallback capacity | Reapprove scope rather than auto-extending assumptions |
| Event-driven | Recall, licence action, quality complaint, legal change, security incident or material product change | Convene clinical/legal/operations review immediately |
Recommended dashboard measures include prescription-receipt rate, clarification rate, time to first patient contact, time from payment to dispatch, on-time delivery, unresolved exceptions, successful refill rate and clinic handling cost. Publish each denominator and exclusion; otherwise supplier comparisons are not reproducible.
Use predefined escalation triggers. A suspected product-quality problem should trigger clinical and quality review and control of affected new routing—not an indiscriminate instruction for patients to stop therapy without medical advice.
Explore the table row by row
A working view of the research
Daily during pilot or disruption
- Review
- Orders due, unacknowledged prescriptions, paid unshipped orders, delivery exceptions
- Action
- Assign owners and escalate time-sensitive cases
Answers stay in this session unless you choose to save. No account needed.
Sources cited on this page
See the section’s source register for the research context.
Section sources →